You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Systematic review and meta-analysis
Intravenous immunoglobulin plus corticosteroids prevent coronary artery abnormalities in Kawasaki disease
  1. Paul Brogan1,
  2. Michael Levin2
  1. 1 University College London, Institute of Child Health, London, UK
  2. 2 Department of Paediatrics, Imperial College London, London, UK
  1. Correspondence to Dr Paul Brogan
    UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK; p.brogan{at}ucl.ac.uk

https://doi.org/10.1136/eb-2013-101264

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart 2013;99:76–82.OpenUrlAbstract/FREE Full Text

    Context

    Kawasaki disease (KD) is a medium vessel vasculitis affecting approximately 8 of 100 000 children under the age of 5 per year in the UK. It is the commonest cause of acquired heart disease in children in developed countries.1 The cause remains elusive. KD is associated with coronary artery aneurysms (CAA) in over 20% of untreated patients; intravenous immunoglobulin (IVIG) reduces CAA frequency to 5%. Only 2–3% of untreated cases die as a result of coronary vasculitis, and KD is an important cause of long-term cardiac disease in …

    View Full Text

    Footnotes

    • Competing interests None.